GlassScriptPhysician profile
Shadi H Sayegh
NPI 1316351174
$6,418.18
in general payments reported to CMS, 2019-2025
38 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $436 · 2021: $1,005 · 2022: $363 · 2023: $1,230 · 2024: $1,234 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,936.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,228.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $814.38 | 2020-2025 | Linzess, Vraylar |
| Abbott Laboratories | $324.87 | 2021-2025 | Freestyle Libre 3, Freestyle Libre, Jeti Peripheral Catheter |
| Amgen INC. | $235.79 | 2019-2025 | Repatha, Repatha, Otezla |
| Horizon Therapeutics Plc | $212.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.56 | 2023-2025 | Jardiance |
| Bausch Health US, LLC | $158.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $158.07 | 2021-2024 | Farxiga, Lokelma |
| Boston Scientific Corporation | $141.75 | 2023 | Rezum Generator |
| Glaxosmithkline, LLC. | $135.71 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $134.95 | 2021 | |
| Xeris Pharmaceuticals, INC. | $131.44 | 2025 | Recorlev |
| Allergan, INC. | $125.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $125.50 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.95 | 2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $121.34 | 2021 | |
| Pharmacosmos Therapeutics INC. | $118.73 | 2023 | Monoferric |
| Amarin Pharma, INC. | $113.29 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $103.55 | 2025 | Gemtesa |
| Exact Sciences Corporation | $96.94 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $96.20 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Ardelyx, INC. | $79.12 | 2025 | Ibsrela |
| Baxter Healthcare | $70.19 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.40 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $40.36 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $39.53 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $38.65 | 2025 | Verquvo |
| Ironwood Pharmaceuticals, INC | $28.02 | 2024 | |
| Lundbeck LLC | $27.09 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $24.49 | 2023 | |
| Pfizer INC. | $21.75 | 2023 | |
| Dexcom, INC. | $21.39 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $16.52 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $14.77 | 2025 | Kristalose |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Evoke Pharma, INC. | $13.48 | 2023 | Gimoti |
| Genentech USA, INC. | $13.14 | 2021 | |
| Antares Pharma, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.